GlassScriptPhysician profile
Jessica MD Korman
NPI 1285860486
$171,432.75
in general payments reported to CMS, 2019-2025
39 companies · $60K in 2025
The $60K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $80.88 · 2021: $800 · 2022: $8,827 · 2023: $38K · 2024: $64K · 2025: $60K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $124K · Food and Beverage: $16K · Travel and Lodging: $15K · Consulting Fee: $5,585 · Education: $29.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124,469.88 |
| Food and Beverage | $15,519.06 |
| Travel and Lodging | $15,335.76 |
| Consulting Fee | $5,585.00 |
| Education | $29.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $83,520.44 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $47,204.34 | 2023-2025 | Zenpep, Vowst |
| Takeda Pharmaceuticals U.S.A., INC. | $17,621.78 | 2019-2025 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $7,197.34 | 2022-2024 | Zeposia |
| Pfizer INC. | $4,143.30 | 2019-2025 | |
| Janssen Biotech, INC. | $3,660.09 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $2,114.98 | 2021-2024 | Zeposia |
| Genzyme Corporation | $672.11 | 2022-2025 | |
| Ardelyx, INC. | $643.79 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $600.73 | 2023-2025 | Omvoh, Zepbound |
| Janssen Scientific Affairs, LLC | $591.75 | 2023-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $486.99 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $478.45 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $394.45 | 2019-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $384.66 | 2019-2025 | Xifaxan, Trulance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $306.46 | 2024-2025 | Vegzelma, Zymfentra |
| Boston Scientific Corporation | $203.43 | 2023-2025 | Overstitch Endoscopic Suturing System |
| Fujifilm Healthcare Americas Corporation | $195.67 | 2022 | |
| Intercept Pharmaceuticals, INC. | $162.03 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $136.96 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $121.82 | 2019-2025 | Suflave, Sutab |
| Fresenius Kabi USA, LLC | $86.60 | 2023 | Idacio |
| Caris Mpi, INC. | $58.80 | 2025 | Mi Cancer Seek |
| Exact Sciences Corporation | $58.45 | 2024 | Cologuard Collection Kit |
| Sandoz INC. | $49.36 | 2023-2024 | Hyrimoz |
| Evoke Pharma, INC. | $34.51 | 2024-2025 | |
| Amgen INC. | $32.25 | 2022 | |
| Pharmacosmos Therapeutics INC. | $30.40 | 2025 | Monoferric |
| Merck Sharp & Dohme LLC | $29.87 | 2019 | |
| Daiichi Sankyo INC. | $29.45 | 2025 | Injectafer |
| Biocon Biologics INC | $27.57 | 2025 | Yesintek |
| Allergan, INC. | $24.60 | 2019 | |
| Ferring Pharmaceuticals INC. | $22.87 | 2020 | |
| Nestle Healthcare Nutrition INC. | $21.07 | 2023 | |
| Madrigal Pharmaceuticals | $20.14 | 2025 | Rezdiffra |
| Organon LLC | $19.35 | 2023 | Renflexis, Hadlima |
| Vivus LLC | $16.81 | 2019 | |
| Endo Pharmaceuticals INC. | $14.62 | 2019 | |
| Ucb, INC. | $14.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Korman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.